Latest Breaking News On - Jordyn tarazi - Page 3 : comparemela.com
CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021
Company to host conference call and webcast at 5:00 p.m. ET
MENLO PARK, Calif., May 03, 2021 (GLOBE NEWSWIRE) CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its first quarter 2021 financial results after the market closes on Monday, May 17, 2021. Management will host a conference call with a slide presentation at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company’s business.
Canada
Jordyn-tarazi
Cohbar-inc
Nasdaq
Conference-call
Slide-presentation
Investor-call
கனடா
நாஸ்டாக்
மாநாடு-அழைப்பு
ஸ்லைடு-ப்ரெஸெஂடேஶந்
முதலீட்டாளர்-அழைப்பு
CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases
MENLO PARK, Calif., March 16, 2021 (GLOBE NEWSWIRE) CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the selection of CB5138-3 as its lead candidate for advancement into IND-enabling activities. CB5138-3 is a CB5138 Analog, a novel class of molecules derived from a natural, mitochondrially encoded peptide source discovered by CohBar, with potential for treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases. IPF is a chronic, progressive, debilitating and usually fatal interstitial lung disease that affects approximately 100,000 people in the U.S. This orphan disease results in fibrotic scarring of the lungs.
Canada
Canadian
Nancy-thompson
Jordyn-tarazi
Steven-engle
Exchange-commission
Cohbar-inc
Nasdaq
Vorticom-inc
Idiopathic-pulmonary-fibrosis
Chief-executive
American-thoracic-society-virtual-annual-meeting